Moleculin Biotech Inc.
(NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did not reach statistical significance.
However, the company noted that both Annamycin treatment arms showed higher remission rates than the control arm in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
An independent monitoring committee recommended continuing the study without eliminating either experimental dose.
Read Also: SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses Annamycin Outperformed Control After One Treatment Cycle The interim analysis, conducted on a full intent-to-treat basis without excluding any patients, showed complete remission (CR) rates of 43% for the 190 mg/m² Annamycin plus high-dose cytarabine (HiDAC) arm and 36% for the 230 mg/m² combination arm.
